Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pathogenic bacteria adhesion to enterocytes refers to the biological process by which pathogenic bacteria attach themselves to the surface of intestinal epithelial cells (enterocytes). This step is considered essential for the initiation of many gastrointestinal infections. The interaction is mediated by bacterial surface structures called adhesins (such as pili or fimbriae), which recognize and bind specific receptor molecules—often glycoproteins or glycolipids—on the host cell membrane[3][5][6]. This attachment enables pathogens like *Escherichia coli*, *Salmonella typhimurium*, and *Shigella* species to resist physical removal from the gut and can trigger downstream effects such as activation of host immune responses (e.g., NF-kB pathway)[1]. Inhibition or disruption of this adhesive interaction can prevent colonization and subsequent infection[3]. While "adhesion" itself is not a single molecule or protein but rather a complex multi-factorial event involving both microbial adhesins and host receptors, it remains an important focus in anti-infective strategies. For example, probiotics may competitively inhibit pathogen binding by occupying available sites on enterocytes[3]. However, there are no approved drugs that directly target "pathogenic bacteria adhesion" as a singular molecular entity. Because "Pathogenic bacteria adhesion to enterocytes" describes a **process** rather than an individual molecule/receptor/protein/gene product, it does not fit standard definitions for therapeutic targets such as enzymes, receptors, ion channels, etc. Therefore: - It should be classified under "Other" for molecular classification. - It is **not** considered a canonical drug target. - The entry is **incorrect** if used where only discrete molecular targets are appropriate. If you need information about specific molecules involved in this process—such as particular bacterial adhesins (e.g., FimH on E. coli) or known human mucosal receptors—please specify so structured data can be provided at that level.
Not applicable as this is a process, not a discrete molecular target
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pathogenic bacteria adhesion to enterocyte.